Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External + Endocavitary Brachytherapy + Concurrent Chemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation

Trial Profile

Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External + Endocavitary Brachytherapy + Concurrent Chemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs CIGB 300 (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Sponsors Elea
  • Most Recent Events

    • 01 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 11 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top